International healthcare giant MSD — formerly Merck Sharp and &Dohme — is to strengthen its Irish operations via an additional €7m investment in its Carlow facility.
The move brings to €227m the company’s total investment in Carlow and will create an additional 20 contract-based jobs in the areas of engineering, automation and project management.
New technological capabilities will also be added at the state-of-the-art facility, which will allow for the manufacture of the firm’s newest pipeline of vaccine and biologic products for treatment across a range of disease areas, including rheumatology, oncology and pneumonia.
MSD currently employs 146 people in Carlow, with a further 60 roles set to be filled this year in quality, IT, production and technical operations.
The new investment work has commenced and is due for completion in July of next year. The company employs 2,300 people in total in Ireland, across eight business units in Dublin, Cork, Wicklow, Tipperary and Carlow.
It has invested over €2.2bn in Ireland since entering the country 50 years ago.
Bryan Meehan, general manager at MSD Carlow, said: “This investment further strengthens MSD Carlow’s position in the company’s global network.
“It also reflects MSD’s continued advancements in the areas of vaccines and biologics. We have made rapid progress over the past 24-months as we move to full production and ultimately, this additional €7m investment will allow us to do more.
“It broadens our reach of products, adds to our production capacity, and enhances our technological capabilities.”
“We are on target to commence full operations at Carlow from next year and estimate that we will produce up to 800 doses of vaccines every minute,” he said.
MSD’s status in Ireland has grown to such an extent that it is now one of the country’s leading exporters and contributes significantly towards making the pharmaceutical industry the country’s leading export sector.
© Irish Examiner Ltd. All rights reserved